NO965336L - Undertrykkelse av tomurcellevekst med syndecan-1 ektodomene - Google Patents

Undertrykkelse av tomurcellevekst med syndecan-1 ektodomene

Info

Publication number
NO965336L
NO965336L NO965336A NO965336A NO965336L NO 965336 L NO965336 L NO 965336L NO 965336 A NO965336 A NO 965336A NO 965336 A NO965336 A NO 965336A NO 965336 L NO965336 L NO 965336L
Authority
NO
Norway
Prior art keywords
syndecan
ectodomes
suppression
cell growth
tumor cell
Prior art date
Application number
NO965336A
Other languages
English (en)
Other versions
NO965336D0 (no
Inventor
Markku Tapani Jalkanen
Markku Mali
Original Assignee
Markku Tapani Jalkanen
Markku Mali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22982439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO965336(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Markku Tapani Jalkanen, Markku Mali filed Critical Markku Tapani Jalkanen
Publication of NO965336L publication Critical patent/NO965336L/no
Publication of NO965336D0 publication Critical patent/NO965336D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår fremgangsmåter for å redusere tumorvekst ved å tilveiebringe ektodo- mene av syndecan.
NO965336A 1994-06-13 1996-12-12 Undertrykkelse av tomurcellevekst med syndecan-1 ektodomene NO965336D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25886294A 1994-06-13 1994-06-13
PCT/FI1995/000344 WO1995034316A1 (en) 1994-06-13 1995-06-13 Suppression of tumor cell growth by syndecan-1 ectodomain

Publications (2)

Publication Number Publication Date
NO965336L true NO965336L (no) 1996-12-12
NO965336D0 NO965336D0 (no) 1996-12-12

Family

ID=22982439

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965336A NO965336D0 (no) 1994-06-13 1996-12-12 Undertrykkelse av tomurcellevekst med syndecan-1 ektodomene

Country Status (17)

Country Link
US (1) US5851993A (no)
EP (1) EP0765167A1 (no)
JP (1) JPH10501258A (no)
KR (1) KR970703782A (no)
AU (1) AU708963B2 (no)
BG (1) BG63622B1 (no)
CA (1) CA2192593A1 (no)
CZ (1) CZ286760B6 (no)
FI (1) FI964997L (no)
HU (1) HU220340B (no)
MX (1) MX9606369A (no)
NO (1) NO965336D0 (no)
NZ (1) NZ288237A (no)
PL (1) PL317658A1 (no)
RU (1) RU2164414C2 (no)
SK (1) SK158496A3 (no)
WO (1) WO1995034316A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
WO1998020121A1 (en) * 1996-11-06 1998-05-14 Children's Medical Center Corporation Transgenic animal expressing a syndecan in the regions of hypothalamus
AU2602200A (en) * 1999-01-08 2000-07-24 Board Of Trustees Of The University Of Arkansas, The Synthetic, highly charged molecules and uses thereof
IL133318A0 (en) * 1999-12-05 2001-04-30 Yeda Res & Dev Proteoglycans and pharmaceutical compositions comprising them
WO2002087609A1 (en) * 2001-05-01 2002-11-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of a cell surface receptor for papillomaviruses
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
US20060134122A1 (en) * 2004-12-16 2006-06-22 Rapraeger Alan C Peptides of syndecan-1 for inhibition of cancer
WO2006105315A2 (en) * 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions and methods for regulating inflammatory responses
KR100694804B1 (ko) * 2005-05-18 2007-03-14 아주대학교산학협력단 작은 헤어핀 ｒｎａ 분자를 포함하는 자궁 내막암 치료또는 예방용 조성물 및 그를 이용한 자궁 내막암 치료 또는예방 방법
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US20080020979A1 (en) 2006-06-09 2008-01-24 Rapraeger Alan C Peptides of Syndecan-1 For Inhibiting Angiogenesis
WO2009105624A2 (en) * 2008-02-21 2009-08-27 Massachusetts Institute Of Technology Simultaneous delivery of receptors and/or co-receptors for growth factor stability and activity
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0448650A4 (en) * 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
WO1990012033A1 (en) * 1989-03-29 1990-10-18 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
GB2245559A (en) * 1990-06-25 1992-01-08 Farmos Oy Bioceramic system for delivery of a bioactive compound.
AU650936B2 (en) * 1991-01-15 1994-07-07 Oy Biotie Therapies Ltd Detection of syndecan content in biological materials such as tissues and body fluids for indications of malignant transformations of cells
WO1993003743A1 (en) * 1991-08-16 1993-03-04 The General Hospital Corporation Method of gene delivery to post-mitotic cells
WO1993005167A1 (en) * 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
DK0671909T3 (da) * 1992-12-01 2001-03-19 Biotie Therapies Corp Syndecanstimulering af cellulær differentiering

Also Published As

Publication number Publication date
MX9606369A (es) 1997-03-29
BG101038A (bg) 1997-10-31
BG63622B1 (bg) 2002-07-31
KR970703782A (ko) 1997-08-09
HUT76535A (en) 1997-09-29
FI964997A7 (fi) 1997-02-13
WO1995034316A1 (en) 1995-12-21
CA2192593A1 (en) 1995-12-21
AU708963B2 (en) 1999-08-19
RU2164414C2 (ru) 2001-03-27
US5851993A (en) 1998-12-22
CZ286760B6 (en) 2000-06-14
CZ355496A3 (cs) 1998-01-14
SK158496A3 (en) 1997-08-06
EP0765167A1 (en) 1997-04-02
HU9603456D0 (en) 1997-02-28
NZ288237A (en) 2001-08-31
NO965336D0 (no) 1996-12-12
HU220340B (hu) 2001-12-28
PL317658A1 (en) 1997-04-28
JPH10501258A (ja) 1998-02-03
FI964997A0 (fi) 1996-12-13
FI964997L (fi) 1997-02-13
AU2739395A (en) 1996-01-05

Similar Documents

Publication Publication Date Title
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
AU1292297A (en) The use of enterobacter cloacae as an endophyte for the control of diseases caused by fungi
NO995646D0 (no) Fremgangsmåte for å öke utbyttet av nukleosidanaloger
GB9406857D0 (en) Improvements in or relating to organic compounds
ATE43848T1 (de) Hydroxysubstituierte peptidverbindungen.
RU94042393A (ru) Галихондрины, родственные соединения и способ лечения опухоли у млекопитающих
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
ES8505338A1 (es) Un metodo de preparar nuevos derivados de benzoil-urea que tienen actividad anti-tumoral
AU7272491A (en) Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
NO912182D0 (no) Fremgangsmaate for forbedring av formasjonspermeabilitet ved anvendelse av klordioksyd.
IT8320709A0 (it) Composto per il trattamento della psoriasi.
AU5686698A (en) Methods for the production of chicken monoclonal antibodies
NO965336D0 (no) Undertrykkelse av tomurcellevekst med syndecan-1 ektodomene
AU4080097A (en) Piperazino derivatives as neurokinin antagonists
FI974640A7 (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
GR3030113T3 (en) Ultrasensitive process for assaying cardiac troponine i
DE69629023D1 (de) Piperazino-derivative als neurokininantagonisten
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
AU5526196A (en) Compositions for the treatment of dandruff
ZA976481B (en) Intermediates for the preparation of 2-imidazolin-5-ones.
FR2720277B1 (fr) Méthode de traitement des cancers par régulation de la protéine P53.
NO973963D0 (no) Fremgangsmåte for å hemme ovariecancer
FR2685717B1 (fr) Jonction-fixation perfectionnee, pour bords de panneaux urbains.
ITMI941283A0 (it) Metodo per migliorare le prestazioni dei codificatori vocali

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application